ストックスクリーナーアプリを入手
13.52
3.29%
-0.46
前日終値:
$13.98
開ける：
$13.4
24時間の取引高:
5,130
Relative Volume:
17.79
時価総額：
$N/A
収益：
$614.00K
当期純損益:
$-76.35M
株価収益率:
-0.2839
EPS:
-47.63
ネットキャッシュフロー:
$-31.51M
1週間 パフォーマンス:
-3.29%
1か月 パフォーマンス:
-7.14%
6か月 パフォーマンス:
-76.92%
1年 パフォーマンス:
+245.37%
1日の値動き範囲:
$13.30
$13.52
1週間の範囲:
$13.30
$13.52
52週間の値動き範囲:
$12.00
$14.75
Finch Therapeutics Group Inc Stock (FNCH) Company Profile
FNCH を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FNCH
Finch Therapeutics Group Inc
|
13.52 | 0 | 614.00K | -76.35M | -31.51M | -47.63 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.89 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
747.18 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.32 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
850.56 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
164.34 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Finch Therapeutics Group Inc Stock (FNCH) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-08-09 | 開始されました | H.C. Wainwright | Buy |
| 2021-04-13 | 開始されました | BofA Securities | Buy |
| 2021-04-13 | 開始されました | Evercore ISI | Outperform |
| 2021-04-13 | 開始されました | Jefferies | Buy |
Finch Therapeutics Group Inc (FNCH) 最新ニュース
Finch Therapeutics Group (NASDAQ:FNCH) Trading Down 3.9% – Should You Sell? - Defense World
North America Human Microbiome Market - MarketsandMarkets
What Makes Finch Therapeutics (FNCH) a Worthy Investment? - Insider Monkey
Global Clostridium Difficile Infections Pipeline Expands With - openPR.com
Aecon Group (TSX:ARE): Valuation Check After Finch West LRT Revenue Service Milestone - simplywall.st
Biotech Companies Hire New Legal Leadership - BioXconomy
PepGen appoints Joseph Vittiglio as chief business and legal officer By Investing.com - Investing.com Australia
PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer - The AI Journal
Pepgen Inc. Appoints Joseph Vittiglio as Chief Business and Legal Officer, Effective December 8, 2025 - marketscreener.com
Crohn’s Disease Outlook Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight - The Globe and Mail
Autism Spectrum Disorder Pipeline Outlook Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight - The Globe and Mail
Finch Therapeutics Group, Inc.Common Stock (OTC:FNCH) Stock Quote - Markets Financial Content
Microbiome Therapeutics Market Size to Hit USD 3,405.99 Million by 2034 - Precedence Research
Collective Growth (OTCMKTS:CGROU) Stock Price Up 7.6% – Here’s What Happened - Defense World
Finch Therapeutics Group (NASDAQ:FNCH) Shares Down 3.5% – What’s Next? - Defense World
MVPs: Kirkland's Adam Alper And Michael De Vries - Law360
Future Outlook: Human Microbiome Therapeutics Market to Hit USD 7.89 Billion by 2034, Growing at 22.80% - openPR.com
Free cash flow per share of Finch Therapeutics Group, Inc. – OTC:FNCH - TradingView
Arquitos Capital Management Q3 2025 Investor Letter - Seeking Alpha
Finch Secures $20 Million to Rebuild Consumer Law from the Ground Up - GlobeNewswire Inc.
United States Human Microbiome Market Set to Surge as Global Industry Projects USD 7.09 Billion Valuation by 2031 - vocal.media
Clostridium Difficile Infections Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Novartis AG, Astellas Pharma, Eli Lilly & Company AstraZeneca - Barchart.com
Microbiome Therapeutics Market Development and Global Outlook - Precedence Research
Clostridium Difficile Infections Pipeline 2025: Latest FDA - openPR.com
Microbiome Therapeutics Market Analysis – Demand, Drivers & Competitive Landscape 2025-2035 - pie-news.com
Hyundai Hope on Wheels and Finch Hyundai donate $140,000 to Children's Health Foundation toward the paediatric oncology program - Yahoo Finance
Analyzing Finch Therapeutics Group (NASDAQ:FNCH) and Genocea Biosciences (NASDAQ:GNCA) - Defense World
Delaware Powerhouse: Richards Layton - Law360
Human Microbiome Global Forecast Report 2025 | Market Set - GlobeNewswire
Clostridioides difficile Infection Market Forecasts by DelveInsight Signal Groundbreaking Growth at a CAGR of 13.5% in the 7MM during the Forecast Period (2025-2034) - The Malaysian Reserve
Clostridium Difficile Infections Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight - openPR.com
BostInnoEpicore Biosystems raises $10M | Starburst sets stage for IPO - The Business Journals
Parsons Corporation $PSN Shares Acquired by Charles Schwab Investment Management Inc. - Defense World
Live Biotherapeutic Product Market Dynamics Shaped by Increasing Awareness and Technological Advancements - openPR.com
Financial Survey: Finch Therapeutics Group (NASDAQ:FNCH) and LadRx (OTCMKTS:CYTR) - Defense World
Microbiome Therapeutics Market Size, Growth, Trends & Forecast (2025–2035) - PharmiWeb.com
Microbiome Therapeutics Market: $2098.3 Mn by 2035 | 30.4% CAGR Growth Analysis - MarketReports.us
Autism Spectrum Disorder Pipeline Appears Robust With 18+ Key - openPR.com
Autism Spectrum Disorder Pipeline 2025: Therapies Under - openPR.com
Clostridium Difficile Infections Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Novartis, Astellas Pharma, Eli Lilly & Company AstraZeneca - Barchart.com
Autism Spectrum Disorder Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism Of Action, Route Of Administration, And Companies By Delveinsight - Menafn.com
5 Best Microbiome Companies (July 2025) - Securities.io
Autism Spectrum Disorder Clinical Trial Analysis: Key - GlobeNewswire
Live Biotherapeutic Products And Microbiome CDMO Market Size, Top Share to 2033 - Straits Research
Clostridium Difficile Infections Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Finch Therapeutics Group (NASDAQ:FNCH) Trading Down 1.2% – Here’s Why - Defense World
Human Microbiome Market Forecasts Report 2025-2030: Key Insights for Navigating Emerging Opportunities - GlobeNewswire
Kesmalea Therapeutics Appoints Industry Veteran Tim Clackson to Board of Directors - BioSpace
Full article: Fecal microbiota transplantation: a tale of two regulatory pathways - Taylor & Francis Online
Arquitos Capital's Largest Holdings For Q1 2025 - Seeking Alpha
Arquitos Capital Management Q1 2025 Investor Letter - Seeking Alpha
Finch Therapeutics Group Inc (FNCH) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
0.22%
大文字化:
|
ボリューム (24 時間):